- Poster presentation
- Open Access
Cardiac surgical aspects of Down syndrome
© Mokryk et al; licensee BioMed Central Ltd. 2013
- Published: 11 September 2013
- Pulmonary Hypertension
- Congenital Heart Disease
- Down Syndrome
- Heart Catheterization
- Hypertensive Crisis
The number of children with Down syndrome (DS) in general population reaches 4,8-7,0%. More than 45,0% of them have different forms of congenital heart diseases (CHD), which is the main death cause in this patient group under two years of age. The purpose of this study was to analyze details of perioperative period in children with DS undergoing CHD repair.
Between 2009 and 2012, 34 consecutive patients with DS and CHD were admitted for medical or surgical treatment. There were 19 (56,0%) boys and 15 (44,0%) girls aged from 4 months to 18 years (20 month ± 2 month). Most common CHD was AVSD, witch had 16 (47.1%).
82,5% (n=28) had hard combined CHD, 82,4% (n=28) - high pulmonary hypertension, all patients - heart failure. In 20,6% (n=6) patients heart catheterization was performed. 6 (20,6%) kids received only medical treatment: 2 (5,8%) - inoperable, 3 (8,8%) medical preparation for surgery due to PH, 1 (2,9%) - no need of surgery. 28 (82,4%) patients were operated on. 26 (92,8%) were open heart cases. 57,6% (n=15) underwent septal defects (ASD, VSD) plasty at median age of 12 ± 3 months. In 42,3% (n=11) AVSD was corrected at median age of 6±1 month. In 7 patients (23,6%) postoperative period was complicated by: DIC syndrome (57,1%), sepsis (28,6%), chylothorax (14,3%). 30-day in hospital mortality occurred in 3 (10,7%) cases: 1 (14,3%) – due to intractable pulmonary hypertensive crisis; 1 (14,3%) – sepsis; 1 (14,3%) – sepsis associated with DIC syndrome. Neither late death nor any residual defects requiring reoperation were detected at follow up.
Surgical correction of CHD in children with DS can be accomplished with acceptable morbidity and mortality rates. Improvement of medical results is possible with special emphasis on preoperative diagnosis and treatment of complications of CHD (PH) and associated pathology (hematologic disorders, infections and immunity status disorders).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.